{"url_path":"/sec/agtx/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 ** **EXECUTIVE COMPENSATION**","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-07-01","source_url":"https://www.sec.gov/Archives/edgar/data/1603345/0001477932-26-004133-index.html","accession_number":"0001477932-26-004133","cik":"0001603345","ticker":"AGTX","issuer_name":"Agentix Corp.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1603345/0001477932-26-004133-index.html","primary_entity_key":"0001603345","primary_entity_name":"Agentix Corp."},"word_count":763,"has_tables":true,"body_markdown":"**ITEM 11.** **EXECUTIVE COMPENSATION**\n\n \n\n**Summary Compensation Table**\n\n \n\nThe table below summarizes all compensation awarded to, earned by, or paid to our officers for all services rendered in all capacities to us as of the years ended March 31, 2026 and March 31, 2025.\n\n \n\n**Name**\n\n \n\n **Year**\n\n \n\n**Salary**\n\n**($)**\n\n \n\n \n\n**Bonus**\n\n**($)**\n\n \n\n**Stock Award**\n\n**($)**\n\n \n\n \n\n**Option Awards**\n\n**($)**\n\n \n\n**Non-Equity**\n\n**Incentive Plan Compensation**\n\n**(****$)**\n\n \n\n**Nonqualified Deferred Compensation Earnings**\n\n**($)**\n\n \n\n**All Other Compensation**\n\n**($)**\n\n \n\n**Total**\n\n**($)**\n \n\nRiazul (Rehan) Huda\n\n \n\n2026\n\n \n\n-0-\n\n \n\n \n\n-0-\n\n \n\n-0-\n\n \n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n \n\n \n\n \n\n2025\n\n \n\n-0-\n\n \n\n \n\n-0-\n\n \n\n-0-\n\n \n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n \n\n  \n\n**STOCK OPTION GRANTS**\n\n \n\nThere were no stock options exercised by the named executive officers as of the end of the fiscal period ended March 31, 2026.\n\n \n\n**EMPLOYMENT AGREEMENTS**\n\n \n\nSalman Hoda Pharma Consulting Inc., an Ontario, Canada, corporation (the “Consultant”), and an entity controlled by Mr. Hoda on the one hand are parties to that certain Consulting Agreement (the “Consulting Agreement”), dated October 1, 2020, pursuant to which the Company pays Consultant a monthly fee of $12,500, and Consultant is obligated to manage our consumer healthcare products in partnership with Bionova Lab and our pharmaceutical programs, as well as certain investor relations activities. The Consulting Agreement, terminates on December 31, 2022 (the “Termination Date”), and automatically renews for one-year periods on each anniversary of the Termination Date unless terminated by either the Company or Consultant not less than 90-days notice prior to a date that the Consulting Agreement terminates. Consultant is also eligible to participate in company incentive plans and reimbursement for expenses incurring in the performance of services for the Company.\n\n \n\nThe Consulting Agreement contains customary terms regarding confidentiality, intellectual property assignment from the Consultant to the Company, and termination by the Company for cause, Termination by the Consultant for good reason, and termination by reason of death or disability. Additionally, either the Company or the Consultant may terminate the Consulting Agreement with 30-days’ notice the parties to the Consulting Agreement.\n\n \n\n \n\n20\n\n*Table of Contents*\n\n \n\n**DIRECTOR COMPENSATION**\n\n \n\nThe following table sets forth director compensation as of March 31, 2026 and 2025:\n\n \n\n**Name**\n\n \n\n \n\n**Fees Earned or Paid in Cash**\n\n**($)**\n\n \n\n \n\n**Stock Awards**\n\n**($)**\n\n \n\n**Option Awards**\n\n**($)**\n\n \n\n**Non-Equity Incentive Plan Compensation**\n\n**($)**\n\n \n\n**Nonqualified Deferred Compensation Earnings**\n\n**($)**\n\n \n\n**All Other Compensation**\n\n**($)**\n\n \n\n**Total**\n\n**($)**\n\n \n\nRiazul (Rehan) Huda (1)\n\n \n\nMarch 31, 2026\n\n \n\n-0-\n\n \n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n \n\n \n\nMarch 31, 2025\n\n \n\n-0-\n\n \n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n-0-\n\n \n\n______\n\n \n\n(1)\n\nAppointed a director of the Company on July 2, 2020.\n\n \n\n**Narrative to Director Compensation Table**\n\n \n\nThe following is a narrative discussion of the material information that we believe is necessary to understand the information disclosed in the previous table.\n\n \n\nNo director receives compensation solely in his or her capacity as a director of the Company. All travel and lodging expenses associated with corporate matters are reimbursed by us, if and when incurred.\n\n \n\n**Director Compensation Policy**\n\n \n\nThe board of directors adopted a Director Compensation Policy (the “Director Compensation Policy”) as set forth below.\n\n \n\nThis policy sets forth compensation payable to each non-employee member of the board of directors.\n\n \n\nNon-employee members of the board of directors of Company shall be eligible to receive cash and equity compensation as set forth in this Director Compensation Policy. The cash compensation and stock awards described in this Director Compensation Policy shall be paid or be made, as applicable, automatically and without further action of the board of directors, to each member of the board of directors who is not an employee of the Company or any parent or subsidiary of the Company (each, an “Independent Director”) who may be eligible to receive such cash compensation or stock awards, unless such Independent Director declines the receipt of such cash compensation or stock awards by written notice to the Chairman of the Board.\n\n \n\nThis Director Compensation Policy shall remain in effect until it is revised or rescinded by further action of the board of directors. The terms and conditions of this Director Compensation Policy shall supersede any prior cash or equity compensation arrangements between the Company and its directors. \n\n \n\n \n\n21\n\n*Table of Contents*\n\n \n\n**Compensation Clawback Policy**\n\n \n\nThe board of directors believes that it is in the best interest of the Company and its stockholders to create and maintain a culture of that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. The board of directors has therefore adopted a compensation recoupment policy, which provides for the recovery of erroneously awarded incentive compensation from the Company’s executive officers in the event of a triggering event, which compensation recoupment policy has been filed as an exhibit to this Annual Report."}